The goal of this project is to exploit the highly potent cytotoxic properties of a novel class of genes, called Fusogenic Membrane Glycoproteins (FMG), for the gene therapy of cancer. Many viruses kill their target cells by causing cell fusion through binding of the viral envelope protein on an infected cell with its cellular receptor on neighboring cells. The result is the formation of large, multi-nucleated syncytia which eventually become non-viable and die. We have used gene transfer of the cDNAs of three different types of FMG to tumor cells. The cytotoxicities of these FMG were consistently greatly superior to that of conventional suicide genes and the local bystander killing effects were at least one log greater than those of the HSVtk/Ganciclovir system. FMG tested so far kill target cells via non-apoptotic mechanisms with the concomitant induction of immune stimulatory signals such as heat shock proteins. We now hypothesize that these properties of FMG-mediated tumor cell killing can be exploited, and enhanced, to generate more effective gene therapies for cancer. We will characterize in detail the mechanisms by which FMG gene transfer leads to cell death to understand what regulates the efficiency of syncytial killing and how to improve it for therapeutic purposes.We will investigate how the mechanisms of syncytial killing can be enhanced in vivo to stimulate potent immune responses against tumor metastases. This will be done by constructing vectors in which additional immune stimulatory genes, such as GM-CSF, are co-expressed with FMG and by generating FMG-induced tumor cell-dendritic cell hybrids for anti-tumor vaccination. We propose to make a series of viral vectors to transfer the cDNAs of different FMG into tumor cells to identify the most effective FMG for the gene therapy of the target disease, in this case malignant melanoma. Finally, we will construct retroviral and adenoviral vectors which incorporate tight transcriptional regulatory elements to allow targeting of FMG expression to melanoma cells to increase the safety of these potent genes for progression to clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA085931-01
Application #
6092893
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Yovandich, Jason L
Project Start
2000-04-01
Project End
2004-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
1
Fiscal Year
2000
Total Cost
$253,980
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kottke, Timothy; Pulido, Jose; Thompson, Jill et al. (2009) Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res 69:7767-74
Hatfield, Paul; Merrick, Alison E; West, Emma et al. (2008) Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J Immunother 31:620-32
Merrick, Alison; Diaz, Rosa Maria; O'Donnell, Dearbhaile et al. (2008) Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naive cytotoxic priming and anti-tumour therapy. Cancer Immunol Immunother 57:897-906
Guedan, S; Gros, A; Cascallo, M et al. (2008) Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication. Gene Ther 15:1240-5
Kottke, Timothy; Sanchez-Perez, Luis; Diaz, Rosa Maria et al. (2007) Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res 67:11970-9
Diaz, Rosa Maria; Galivo, Feorillo; Kottke, Timothy et al. (2007) Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67:2840-8
Qiao, J; Moreno, J; Sanchez-Perez, L et al. (2006) VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Gene Ther 13:1457-70
Errington, Fiona; Bateman, Andrew; Kottke, Tim et al. (2006) Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin Cancer Res 12:1333-41
Fu, Xinping; Tao, Lihua; Jin, Aiwu et al. (2003) Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 7:748-54
Ahmed, A; Jevremovic, D; Suzuki, K et al. (2003) Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene Ther 10:1663-71

Showing the most recent 10 out of 15 publications